Equity Details
Price & Market Data
Price: $74.81
Daily Change: +$0.25 / 0.33%
Daily Range: $73.13 - $75.23
Market Cap: $10,156,997,632
Daily Volume: 2,400,092
Performance Metrics
1 Week: -2.96%
1 Month: 12.13%
3 Months: 15.36%
6 Months: 24.35%
1 Year: 132.8%
YTD: 17.74%
About Cytokinetics, Incorporated (CYTK)
Get the full picture of Cytokinetics, Incorporated (CYTK). Price: 74.81, daily change: +$0.25 / 0.33%. Market cap: 10,156,997,632. All performance metrics from 1-week to 1-year are here.
Company Details
Employees: 673
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.